NightstaRx (Nightstar), a fresh spin-out from the University of Oxford, has launched with £12m ($20m) in backing from Syncona, a subsidiary of charity investor the Wellcome Trust.

The company is focused on the development and commercialisation of therapies for degenerative conditions which affect vision. The first retinal dystrophy Nightstar will focus on is a gene therapy for choroideremia, an inherited form of blindness.

The treatment uses a modified virus, AAV.REP1, to correct genetic information of cells in the eye’s retina.…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?